GlobeNewswire Inc | May 17, 2021 07:30AM EDT

May 17, 2021

Achieves 32% sequential increase in revenue for Q1 2021 versus Q4 2020

Reports approximately $17 million of cash and cash equivalents as of March 31, 2021

ROSELAND, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the first quarter ended March 31, 2021.

Arjan Haverhals, President of Milestone Scientific and CEO of Wand Dental Inc., stated, "I am pleased to report that our revenue for the first quarter of 2021 increased more than 61% to $2.9 million versus $1.8 million for the same period last year. We also achieved a strong sequential increase in sales of 32% versus the fourth quarter of 2020. We continue to carefully manage our operating expenses and significantly reduced our net loss during the quarter. Importantly, our dental segment remains cash flow positive on a standalone basis with continued growth opportunities. Our primary focus has been, and continues to be, the commercialization of the CompuFlo Epidural System within our medical segment. Specifically, now that we have penetrated several medical institutions with our CompuFlo Epidural Instrument and CathCheck System, we are aggressively building our sales and marketing organization as we prepare for the next phase of our growth. We believe these latest commercial orders from several recognized hospitals is validation that our technology provides a level of safety and efficiency not currently available to medical professionals using conventional syringes. We truly believe 2021 will be a transformative year for our medical business and an important turning point as we execute on our goal of establishing our medical instruments and disposables as the new standard of care for epidural procedures in labor and delivery.

Leonard Osser, Interim Chief Executive Officer, further noted, Our strong balance sheet with approximately $17 million of cash and cash equivalents as of March 31, 2021 provides us substantial resources and the ability to accelerate our sales and marketing activities around both our dental and medical instruments. It also allows us to advance the development and commercialization of other indications for our proprietary DPS Dynamic Pressure Sensing Technology, which we believe represent further growth opportunities for our company. Additionally, last week we announced that we are promoting Arjan Haverhals to CEO and hired Scott Kahn as our new CFO. Arjan has already proven his exceptional leadership, and Scott will be instrumental, not only overseeing our financial infrastructure, but also helping us to increase investor awareness as we execute on key milestones. I look forward to staying actively involved as Vice Chairman of the Board and continuing to oversee our China operations.

For the three months ended March 31, 2021 and 2020, revenues were approximately $2.9 million and $1.8 million, respectively. Dental revenues increased by approximately $1.0 million, due to the re-opening of dental offices throughout the country, the rest of the world, and China. Gross profit for the first quarter ended March 31, 2021 was $1.8 million or 62% of revenue versus $1.3 million or 71% of revenue for first quarter ended March 31, 2020. The decrease in the gross profit margin is due to the lower margin in sales to China. Operating loss for the three months ended March 31, 2021 was approximately $(1.0) million versus approximately $(1.6) million for the first quarter ended March 31, 2020. Net loss was approximately $(1.0) million, or $(0.01) per share for the three months ended March 31, 2021, versus net loss of $(1.6) million, or $(0.03) per share, for the comparable period in 2020.

Conference Call

Milestone Scientifics executive management team will host a conference call today at 11:00 A.M. Eastern Time to discuss the Companys financial results for the first quarter ended March 31, 2021, as well as the Companys corporate progress and other developments.

The conference call will be available via telephone by dialing toll free 1- 877-407-0778 for U.S. callers or 201-689-8565 for international callers. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2306/41369 or on the Companys website at https://www.milestonescientific.com/.

An audio replay of the of the call will be available through May 31, 2021 and can be accessed by dialing 877-481-4010 for U.S callers or 919-882-2331 for international callers and by entering the access code: 41369.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs and develops innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestones proprietary DPS Dynamic Pressure Sensing technology is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2020. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

(tables follow)

MILESTONE SCIENTIFIC AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(UNAUDITED) March 31, 2021 December 31, 2020 ASSETS Current assets: Cash and cash equivalents $ 16,950,710 $ 14,223,917 Accounts receivable, net 978,761 1,080,656 Accounts receivable, related party net 267,300 - Prepaid expenses and other current assets 688,820 415,915 Inventories, net 2,020,549 2,420,179 Advances on contracts 753,197 414,202 Total current assets 21,659,337 18,554,869 Furniture, fixtures and equipment, net 27,074 30,729 Intangibles, net 317,896 329,249 Right of use assets 612,576 632,453 Other assets 24,150 24,150 Total assets $ 22,641,033 $ 19,571,450 LIABILITIES AND STOCKHOLDERS? EQUITY Current liabilities: Accounts payable $ 694,044 $ 482,972 Accounts payable, related party 184,360 385,138 Accrued expenses and other payables 1,178,907 824,454 Accrued expenses, related party 382,627 586,734 Current portion of finance leases 7,977 7,796 liabilitiesCurrent portion of operating lease 73,596 72,031 right-of-use liabilitiesDeferred profit, related party 241,288 242,589 Note payable 276,180 276,180 Total current liabilities 3,038,979 2,877,894 Finance lease liabilities 26,544 28,607 Operating lease liabilities 538,421 557,981 Total liabilities $ 3,603,944 $ 3,464,482 Commitments and contingencies Stockholders? equity Common stock, par value $.001; authorized85,000,000 shares; 66,591,883 sharesissued and 66,558,550 shares outstanding 66,591 64,171 as of March 31, 2021; 64,171,435 sharesissued and 64,138,102 shares outstandingas of December 31, 2020?Additional paid in capital 121,848,254 117,934,696 Accumulated deficit (101,858,826 ) (100,885,957 )Treasury stock, at cost, 33,333 shares (911,516 ) (911,516 )Total Milestone Scientific Inc. 19,144,503 16,201,394 stockholders' equityNoncontrolling interest (107,414 ) (94,426 )Total stockholders? equity 19,037,089 16,106,968 Total liabilities and stockholders? $ 22,641,033 $ 19,571,450 equity

MILESTONE SCIENTIFIC AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED) For the three months ended March 31, 2021 2020 Product sales, net $ 2,924,707 $ 1,811,386 Cost of products sold 1,122,413 527,250 Gross profit 1,802,294 1,284,136 Selling, general and administrative expenses 2,749,299 2,748,043 Research and development expenses 16,444 107,480 Depreciation and amortization expense 20,924 37,219 Total operating expenses 2,786,667 2,892,742 Loss from operations (984,373 ) (1,608,606 )Interest expense, net (2,535 ) (4,097 )Loss before provision for income taxes and (986,908 ) (1,612,703 )net of equity investmentsProvision for income taxes (250 ) (250 )Loss before equity in net earnings of equity (987,158 ) (1,612,953 )investmentsIncome from China Joint Venture 1,301 - Net loss (985,857 ) (1,612,953 )Net loss attributable to noncontrolling (12,988 ) (12,738 )interestsNet loss attributable to Milestone Scientific $ (972,869 ) $ (1,600,215 )Inc. Net loss per share applicable to common stockholders?Basic (0.01 ) (0.03 )Diluted (0.01 ) (0.03 ) Weighted average shares outstanding and to be issued?Basic 66,578,435 49,730,252 Diluted 66,578,435 49,730,252

Contact:David Waldman or Natalya RudmanCrescendo Communications, LLCEmail: mlss@crescendo-ir.comTel: 212-671-1020